10-Q: SS Innovations Reports Q1 2026 Revenue Growth

SS Innovations International, Inc. reported a significant increase in revenue for the first quarter of 2026, driven by strong system and instrument sales, while also addressing ongoing operational and financial considerations.

Summary

• SS Innovations International, Inc. reported total revenues of $11.1 million for the three months ended March 31, 2026, a substantial increase from $5.1 million in the same period of 2025.
• System sales were the primary driver, reaching $9.6 million, up from $4.5 million in Q1 2025. Instrument sales also saw a significant jump to $1.15 million from $0.48 million.
• The company reported a net loss of $3.58 million for the quarter, an improvement from a net loss of $5.68 million in Q1 2025.
• Cash and cash equivalents increased significantly to $15.98 million from $3.21 million at the end of 2025, with total cash, cash equivalents, and restricted cash at $24.01 million.
• The company continues to focus on its SSi Mantra surgical robotic system and expanding its global presence, with 99% of revenue generated in India during the quarter.
• Management is actively seeking further funding to scale operations and meet longer-term capital needs, acknowledging that current resources are not expected to be sufficient for the next twelve months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive sentiment. While revenue growth is strong and the net loss has narrowed, the persistent losses and the explicit mention of substantial doubt regarding the company's ability to continue as a going concern temper the positive outlook.

Positives

• Total revenue more than doubled year-over-year, reaching $11.1 million in Q1 2026 compared to $5.1 million in Q1 2025.
• System sales increased by 113% to $9.58 million, indicating strong market adoption of the SSi Mantra system.
• Instrument sales more than doubled to $1.15 million, supporting the installed base of robotic systems.
• Gross profit improved significantly to $5.33 million from $1.09 million, demonstrating better cost management relative to revenue.
• Net loss narrowed to $3.58 million from $5.68 million, showing progress in operational efficiency.
• Cash and cash equivalents saw a substantial increase, rising to $15.98 million from $3.21 million.
• The company successfully completed a private placement raising $18.45 million in net proceeds in March 2026.
• India remains the dominant market, contributing 99% of revenue, highlighting strong domestic traction.

Negatives

• The company continues to incur significant net losses, totaling $3.58 million for the quarter.
• Stock compensation expense increased by 32% to $3.14 million, impacting profitability.
• Selling, general, and administrative expenses rose by 32% to $4.50 million.
• The company acknowledges substantial doubt about its ability to continue as a going concern, despite recent funding.
• Management is actively seeking further funding, indicating current cash resources are insufficient for the next twelve months.
• Material weaknesses in internal control over financial reporting persist, including lack of written documentation and insufficient segregation of duties.

Risks

• The company's ability to continue as a going concern is subject to successfully raising additional funding.
• Failure to obtain regulatory approvals in key markets like the US and EU could hinder expansion plans.
• The company faces ongoing challenges with material weaknesses in internal controls over financial reporting.
• Dependence on related parties for funding operations remains a factor.
• The company's financial performance is dependent on increasing awareness and adoption of robotic surgery, which can be influenced by market dynamics and competitor actions.

Future Outlook

The company expects to require substantial funds for scaling operations, capital expenditure for in-house machining and tooling, and continued research and development. Management is actively seeking further funding through private or public offerings, as current cash resources are not expected to be sufficient for the next twelve months. The company plans to use proceeds from the recent private placement for working capital, growth initiatives, and market entry preparations in the US and EU.

Management Comments

• Management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.
• While management believes it will be successful in its capital formation and planned expansion, there can be no assurance that additional equity capital will be raised or that the company will achieve profitability.
• The company's financial performance is largely driven by increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons, and the affordability and accessibility of surgical robotic technology.
• Our manufacturing operations being based in India derive significant operating cost advantages which help us in having lower costs of production which eventually helps us make our surgical robotic system cost effective and relatively affordable.

Industry Context

StockSavvy.ai notes that SS Innovations International is operating in the rapidly evolving surgical robotics market, a sector characterized by high R&D investment and significant regulatory hurdles. The company's strategy of focusing on affordability and accessibility, particularly in emerging markets like India, differentiates it from some established players. However, the path to profitability remains challenging, with a continued reliance on external financing and the need for successful market penetration in regulated regions like the US and EU.

Comparison to Industry Standards

• While specific comparable companies are not detailed in the filing, the surgical robotics market is dominated by players like Intuitive Surgical, Medtronic, and Johnson & Johnson, which have established global footprints and significant revenue streams. SS Innovations' revenue of $11.1 million for the quarter is considerably smaller than these established leaders.
• The company's focus on affordability is a strategic differentiator, as many existing robotic surgery systems are prohibitively expensive for many healthcare systems, particularly in developing economies.
• The reported net loss of $3.58 million, while an improvement, is typical for companies in the early commercialization phase of complex medical devices, where significant investment in R&D, manufacturing, and market access is required.

Management Changes

Corporate Governance

Legal Proceedings

• The company's Indian subsidiary received a draft assessment order related to a proposed transfer pricing adjustment of $521,329 for the assessment year 2021-22. The Dispute Resolution Panel granted partial relief, reducing the adjustment to $504,916. The company has appealed to the Income Tax Appellate Tribunal (ITAT) and believes its position will be sustained.

Related Party Transactions

• Expenses incurred on behalf of affiliates such as Srivastava Robotic Surgery Pvt Ltd, SS International Centre for Robotics Surgery Pvt Ltd, Sudhir Srivastava Medical Innovations Pvt Ltd, and Telegnosis Pvt Ltd.
• Expenses incurred on behalf of the company by Sudhir Prem Srivastava, M.D.
• Stock compensation expenses related to 2016 Stock Incentive Plans for Anup Sethi, Barry F. Cohen, Dr. S.P. Somashekhar, Sudhir Prem Srivastava, M.D., Vishwajyoti P. Srivastava M.D, and Milan Rao.
• Consultancy charges, sitting fees, and other perquisites paid to Anup Sethi, Barry F. Cohen, Sudhir Prem Srivastava, M.D., Vishwaivoti P. Srivastava, M.D, Milan Rao, Dr. Frederic H Moll, Dr. S.P. Somashekhar, Mr. Tim Adams, and Mylswamy Annadurai.
• Proceeds from Private Investment in Public Equity from Sushruta Private Limited ($2,000,000), Mr. Tim Adams ($1,197,000), and Dr. Frederic H Moll ($2,000,000).
• Proceeds from notes issued to Sushruta Private Limited ($28,000,000 in 2025).
• Interest accrued on notes from Sushruta Private Limited.
• Conversion of notes into common stock by Sushruta Private Limited.
• Outstanding balances receivable/payable with related parties including Barry F. Cohen, Milan Rao, Cardio Bahamas, SSI PTE Singapore, Sudhir Prem Srivastava, M.D., Sudhir Srivastava Medical Innovations Pvt Ltd, Telegnosis Private Limited, and Sushruta Private Limited.

Stakeholder Impact

• Shareholders: The company's continued reliance on equity financing and the ongoing net losses may impact share value. However, the revenue growth and successful capital raise are positive indicators.
• Employees: Increased stock compensation expense suggests a focus on employee retention and incentives, potentially benefiting morale and performance.
• Creditors: The company's ability to service its debt obligations is contingent on its ability to secure future funding, posing a potential risk to creditors if capital raising efforts are unsuccessful.
• Management: The company's management is actively engaged in fundraising and operational scaling, facing the challenge of balancing growth with financial sustainability and addressing internal control weaknesses.

Next Steps

• Continue to scale operations and finance research and development.
• Seek further funding through private or public offerings.
• Advance growth initiatives in India and other global markets.
• Prepare for market entry into the United States and European Union markets.
• Continue efforts to obtain US FDA and EU CE mark approvals.

Key Dates

Recommendation

The company shows strong revenue growth, indicating increasing market traction for its surgical robotic systems. However, persistent net losses, substantial doubt about going concern, and material weaknesses in internal controls present significant risks. While the recent capital raise and future fundraising plans are positive, the path to profitability is not yet clear. A 'hold' recommendation is appropriate, pending further evidence of sustained profitability and resolution of internal control issues.

Keywords

SS Innovations International, Form 10-Q, Quarterly Report, Surgical Robotics, SSi Mantra, Medical Devices, Revenue Growth, Net Loss, Financial Statements, SEC Filing